School of Medicine, University of Glasgow, Western Infirmary, Glasgow G12 8QQ, UK.
Reprod Biomed Online. 2011 Oct;23(4):411-20. doi: 10.1016/j.rbmo.2011.06.011. Epub 2011 Jun 28.
Anti-Müllerian hormone (AMH) is set to dominate reproductive endocrinology because of its unique relationship with the ovarian reserve. To date half of the published articles have used the Diagnostic Systems Lab (DSL) assay and the other half the Immunotech (IOT) assay. Unfortunately, these assays utilize two different primary antibodies against AMH and different standards, and consequently the crude values reported can differ substantially, with the IOT assay giving values for AMH that are higher than those obtained with the DSL assay. With the recent consolidation of these two companies by Beckman Coulter, and their sole ownership of the patent to measure mammalian AMH, there is finally a single commercially available assay - the AMH Gen II assay, which will fully replace the DSL and IOT assays. The aim of this article is to briefly focus on the different assays for AMH evaluation in order to give readers hopefully helpful suggestions for a correct interpretation of the AMH measurement. A brief overview on the development and performance characteristics of the new assay, how it relates to previous values and previously developed nomograms and where the future lies for AMH is also provided.
抗缪勒管激素（AMH）因其与卵巢储备功能的独特关系，将主导生殖内分泌学。迄今为止，半数已发表的文章使用诊断系统实验室（DSL）检测法，而另一半则使用 Immunotech（IOT）检测法。不幸的是，这些检测法使用针对 AMH 的两种不同的主要抗体和不同的标准，因此报告的原始值差异很大，IOT 检测法给出的 AMH 值高于 DSL 检测法。随着这两家公司最近被贝克曼库尔特（Beckman Coulter）合并，以及他们对测量哺乳动物 AMH 的专利的独家所有权，终于有了一种单一的商业上可获得的检测法 - AMH Gen II 检测法，它将完全取代 DSL 和 IOT 检测法。本文的目的是简要介绍 AMH 评估的不同检测法，希望为读者正确解释 AMH 测量提供有用的建议。还简要概述了新检测法的开发和性能特点、它与以前的数值和以前开发的诺莫图的关系，以及 AMH 的未来方向。
